S
Sol-Gel Technologies Ltd. (SLGL)
NCM – Real Time Price. Currency in USD
67.21
-2.69 (-3.85%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
67.21
-2.69 (-3.85%)
At close: May 12, 2026, 4:00 PM EDT
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Name | Position |
|---|---|
| Dr. Itzik Yosef | Chief Operating Officer |
| Mr. Eyal Ben-Or | Chief Financial Officer |
| Mr. Michael Glezin | Chief Business Officer |
| Mr. Moshe Arkin | CEO & Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-03-24 | 6-K | zk2634892.htm |
| 2026-03-19 | POS AM | zk2634875.htm |
| 2026-03-19 | 20-F | zk2634571.htm |
| 2025-12-17 | 6-K | zk2534121.htm |
| 2025-11-20 | 6-K | zk2534051.htm |
| 2025-11-14 | 6-K | zk2534012.htm |
| 2025-09-25 | 6-K | zk2533806.htm |
| 2025-09-04 | 6-K | zk2533751.htm |
| 2025-08-15 | POS AM | zk2533667.htm |
| 2025-05-08 | 6-K/A | zk2533144.htm |